Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract Cancer.

Content Provider	Europe PMC
Author	Kang, Jihoon Lee, Ji-Young Lee, Sunmin Kim, Danbee Lim, Jinyeong Jun, Ha Ra Jeon, Seyeon Kim, Young-Ae Park, Hye Seon Kim, Kyu-pyo Chun, Sung-Min Lee, Hee Jin Yoo, Changhoon
Copyright Year	2023
Abstract	PurposeBiliary tract cancers (BTCs) are rare and show a dismal prognosis with limited treatment options. To improve our understanding of these heterogeneous tumors and develop effective therapeutic agents, suitable preclinical models reflecting diverse tumor characteristics are needed. We established and characterized new patient-derived cancer cell cultures and patient-derived xenograft (PDX) models using malignant ascites from five patients with BTC.Materials and MethodsFive patient-derived cancer cell cultures and three PDX models derived from malignant ascites of five patients with BTC, AMCBTC-01, -02, -03, -04, and -05, were established. To characterize the models histogenetically and confirm whether characteristics of the primary tumor were maintained, targeted sequencing and histopathological comparison between primary tissue and xenograft tumors were performed.ResultsFrom malignant ascites of five BTC patients, five patient-derived cancer cell cultures (100% success rate), and three PDXs (60% success rate) were established. The morphological characteristics of three primary xenograft tumors were compared with those of matched primary tumors, and they displayed a similar morphology. The mutated genes in samples (models, primary tumor tissue, or both) from more than one patient were TP53 (n=2), KRAS (n=2), and STK11 (n=2). Overall, the pattern of commonly mutated genes in BTC cell cultures was different from that in commercially available BTC cell lines.ConclusionWe successfully established the patient-derived cancer cell cultures and xenograft models derived from malignant ascites in BTC patients. These models accompanied by different genetic characteristics from commercially available models will help better understand BTC biology.
ISSN	15982998
Journal	Cancer Research and Treatment : Official Journal of Korean Cancer Association
Volume Number	55
PubMed Central reference number	PMC9873337
Issue Number	1
PubMed reference number	35410113
e-ISSN	20059256
DOI	10.4143/crt.2021.1166
Language	English
Publisher	Korean Cancer Association
Publisher Date	2022-04-06
Access Restriction	Open
Rights License	This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2023 by the Korean Cancer Association
Subject Keyword	Ascites Biliary tract neoplasms Cancer cell cultures Patient-derived xenograft High-throughput nucleotide sequencing
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology